Double attack on liver cancer: does adding RFA to TACE improve survival?
NCT ID NCT02435953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone or TACE followed by RFA. The study measured progression-free survival, overall survival, and tumor response rates to see if the combination is more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TACE (chemoembolization) and RFA (radiofrequency ablation)
What this could lead to
If successful, combining TACE with RFA could improve survival and tumor control for people with intermediate-stage liver cancer compared to TACE alone.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients. The combination may increase side effects or not show a clear benefit over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,
Guangzhou, Guangdong, 500060, China